Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap1.23B
Enterprise Value1.13B
XLO
(NASDAQ)Xilio Therapeutics, Inc.
$8.51-- (--)
Loading... - Market loading
Xilio Therapeutics (XLO) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)38.42
Forward Price/Sales12.81
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue35.39
EV/Earnings-19.24
EV/EBITDA-26.68
EV/EBIT-25.71
EV/FCF-64.02
Stock Price
Current price, 52-week range, and moving averages
Current Price$8.51
1-Day Change0.83%
52-Week High$10.42
52-Week Low$0.62
52-Week Change1145.23%
YTD Change-9.83%
1-Year Change1059.74%
50-Day MA$7.91
200-Day MA$3.51
Avg Volume (30 day)26.00K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding144.11M
Book Value per Share$-0.06
Net Cash per Share$0.71
FCF per Share$-0.12
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin50.73%
EBITDA Margin (ttm)-132.63%
EBIT Margin (ttm)-137.64%
Operating Margin (ttm)-137.64%
Pretax Margin (ttm)-183.90%
Profit Margin (ttm)-183.90%
FCF Margin (ttm)-55.28%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Assets (ttm)-43.75%
Return on Capital Employed (ttm)-56.64%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue31.80M
Gross Profit16.13M
Operating Income-43.77M
Pretax Income-58.49M
Net Income-58.49M
EBITDA-42.18M
EBIT-43.77M
Diluted EPS$-0.41
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-17.15M
Capital Expenditures429.00K
Free Cash Flow-17.58M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)133.69M
Cash & Securities (mrq)103.76M
Net Cash (mrq)102.46M
Net Cash per Share$0.71
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)7.26M
Working Capital (mrq)67.69M
Total Equity (mrq)-8.10M
Book Value per Share$-0.06
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.20
Quick Ratio (mrq)2.20
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-4.79%
FCF Yield-1.44%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score0.44
Piotroski F-Score4/9
Frequently Asked Questions About Xilio Therapeutics Statistics
What are the key financial metrics for XLO?
Xilio Therapeutics, Inc. (XLO) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is XLO's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Xilio Therapeutics is overvalued or undervalued.
How do I read XLO's profitability ratios?
Xilio Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do XLO's debt ratios indicate?
The financial health section shows Xilio Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is XLO's dividend analysis?
The dividend section covers Xilio Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.